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Genotype and Phenotype in Ehlers-Danlos Syndrome Type IV 
Smith el "I (p. 241) show that mutati ons in the region of the 
COL3Al gene coding for the triple helix affect the size and 
d is tribution of dermal co ll agen fibril s in patients with Eh lers-Danlos 
Syndrome (EDS) Type IV. T hese patients have extreme ly fra gil e 
tissues and arc at hi gh ri sk for arteria l, bowel. and uterin e rupture, 
a nd their skin is thin and bruises easily. T he authors note that both 
(i) the amount and size of colJagen fibril s in the dermis and also (ii) 
the ex tent of dilation o f the rough endoplasmic reticulum (RE R) in 
fibro blasts were quite variable in different patients and wondered 
w h ether the variability could be related to the type or position of 
[he mutation. To stud y this question, they compared the diameters 
of colJagen ~ibrils by electron mi croscopy in patients with known 
mutations. I30th substitutions for glycine and exon skipping muta-
tions in the carboxyl-terminal end of the trip le heli x were associ-
ated with reduced fibril diam eter and dilated RER. (Di lated R E R 
is tho ught to be rel ated to defective secretion of newly synth esized 
abnorma l coll agen.) In contrast, chan ges ncar the atni no-tennina l 
end of the trip le helical domain w ere associa ted with variable 
diam eters of th e fibrils and less evidence of intracellul ar retention of 
the abnorma l protein . T he J'esults suggest that different typ es of 
structural changes in colla gen fibrils ma y refl ect the specific l11uta-
tions; i.e. , the alterations m ay be characteristic of the mutation. 
Beca use the EDS phe notype was simi lar in the patients studied, 
however, the redu ced amount o f normal type III collagen. not the 
variati on in fibri l diameter, may be the m os t important f.1 c tor in 
determining th e clini ca l findings. 
A Possible Role for TIMP-l in Scleroderma 
Kikuchi el al (p. 281) report th at T IMP-1may be an alltocrill c growth 
fac tor, that is , a f.'1ctor both secreted by and acting on adjacent 
fibro blasts, in scleroderm a. Severa l reports have described e levated 
mitogenic acti vity for dermal fibroblasts in the sera of scleroderma 
patients. R ecentl y, T IMP-l , which antagon izes collagenase activ-
ity, has been shown to be mitogeni c for dermal fibroblasts. T he 
a uthors thought T IMP-1 , which was elevated in sera of sclero-
derma patients. mig ht be in vo lved in the activation of fibroblasts 
derived fi'om scleroderma skin and therefore in vestigated both the 
mitogenic response to T IMP-l and also T IMP-l exp ression in 
scleroderma fibroblasts. T he mitogenic response to TIMP-1 in 
scleroderma fibroblasts was in creased over that in contro ls , and 
antibod y to TIMP-'I blocked the basa l mitogenic activity ofsclero-
derma fibroblasts, supporting a role for TIMP-l ill the regulation of 
fibrob last proliferation. Scleroderma fibro blasts produced increased 
amounts of T IM P-1 protein and m R.N A . T ransfo rming growth 
facto r-{3 (TGF-(3) , thou ght to be a critical cytokine in fibrosis , is 
also a potent indu cer of T IM P-1. and the auth ors fo und that TGF-f3 
upregulated T IMP- l production in normal fibro blasts. but not in 
sclero derma tibrobl as ts. T hi s might re fl ect the earl y excessive 
exposure to TGF-{3 ill /Ii llo in scleroderma fibroblasts. T hese ob-
servations suggest that T IMP-l might be invo lved not o nl y in the 
co ll agen accumu lation , but also in the fibro blast proliferation 
accompanying fibro sis in scleroderma. Antagoniz ing TIMP-1 might 
reclu ce dermal fibrosi s. 
Modulating Fibrosis 111 Wounded Skin 
Meisler el nl (p. 285) ha ve found that dexamethasone abrogates the 
fibrogenic effect of tran sfo rmin g growth f.1cto r-{3 (TGF-{3). I t had 
been known for some time that dexamethaso ne can antagonize the 
effects of TGF-f3. Since TGF-f3 is known to in crease co llagen 
synthesis while dexamethason e decreases it, the investigators asked 
w h e ther dexamethason e could prevent the fibrosis stimulated by 
TGF-{3. When sma ll sponges were pla ced ill the skin of rats and 
exam.inecl for m easures of collagen content, dexamethasone wa s 
found to block the increase in hyd roxypro line produced by TGF- {3. 
Similar results were found when granulation tiss ue fibroblasts were 
treated with TGF-FJ and dexametha sone . "Bimodal" therapy in-
volving the usc of both TGF-/3 and dexamethasone ma y promote 
wou nd healing w ithout the excessive sca rring tha t re fl ec ts in creased 
c.o llagen deposition and migh t be used to enhan ce no rmal repaiJ·. 
for example in second-degree burns. 
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